Aeolus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported contract contract revenues of $63,000 compared with $4,983,000 for the same period last year. Loss from operations was $784,000 compared with income from operations of $1,576,000 for the same period last year. Net loss was $784,000 or $0.01 diluted per share compared with net income of $1,576,000 or $0.01 diluted per share for the same period last year.

For the nine months, the company reported contract revenue of $2,177,000 compared with $7,214,000 for the same period last year. Loss from operations was $2,194,000 compared with income from operations of $445,000 for the same period last year. Net loss was $2,194,000 or $0.02 diluted per share compared with net income of $445,000 or $0.00 diluted per share for the same period last year. Net cash used in operating activities was $1,121,000 compared with cash generated from operating activities of $403,000 for the same period last year.